Evaluating the Efficacy and Safety of Topical Difluprednate in Patients with Chronic Central Serous Chorioretinopathy.

The difluprednate group showed significantly greater reductions in subfoveal choroidal thickness (subfoveal choroidal thickness) and improvements in 3-mm microperimetry thresholds compared with the observation group (p = 0.012 and p = 0.022, respectively).

It also demonstrated the largest decrease in central macular thickness, although this was not statistically significant (p = 0.19).

Ocular hypertension developed in 30% of difluprednate-treated eyes and was controlled with topical antiglaucoma medication.